HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN

This article was originally published in The Rose Sheet

Executive Summary

Continued support of NTP alpha and beta hydroxy acids and the online Cosmetics Voluntary Reporting Program among cosmetic program accomplishments completed during fiscal year, according to center's 2000 Report Card. Continued support of EU-U.S. bilateral program and Cosmetics Harmonization and International Cooperation initiative also noted as an accomplishment. Substantial progress was made in the areas of diethanolamine risk assessment and AHA labeling guidance, according to FDA. AHA labeling topped the cosmetics office priorities list when it was released in February (1"The Rose Sheet" Feb. 14, 2000, p. 8). Overall, CFSAN completed 78% of its "A" list priorities, achieving its goal of 75%, agency says

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008803

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel